SCHEMBL2126941

SCHEMBL2126941

CC(C)(C)c1cc(-c2ccc[nH]c2=O)cc(NC(=O)c2ccc(NS(C)(=O)=O)cc2)c1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.53
ALDH1A1 P00352 4/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
ABL1 P00519 1/20 0.41
HPGD P15428 4/20 0.41
MAPK10 P53779 1/20 0.41
BTK Q06187 1/20 0.41
KIT P10721 1/20 0.41
SRC P12931 1/20 0.41
FLT3 P36888 1/20 0.41
ITK Q08881 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
EPHX2 P34913 3/20 0.40
NR1H4 Q96RI1 1/20 0.39
MAPK1 P28482 1/20 0.39
NAMPT P43490 1/20 0.38
PLA2G7 Q13093 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542369 0.88 CYP3A4 (0.65) CYP3A4ALDH1A1MAPTLMNAABL1
SCHEMBL1542741 0.86 ITK (0.44) CYP3A4ALDH1A1ABL1BTKKIT
SCHEMBL2127623 0.79 CYP3A4 (0.53) CYP3A4ALDH1A1ABL1BTKPLA2G7
SCHEMBL2128083 0.79 CYP3A4 (0.48) CYP3A4ALDH1A1MAPTLMNAHPGD
SCHEMBL2127612 0.79 CYP3A4 (0.58) CYP3A4ALDH1A1ABL1BTKTRPV1
SCHEMBL2129460 0.78 CYP3A4 (0.59) CYP3A4ALDH1A1ABL1HPGDMAPK10
SCHEMBL2129383 0.77 CYP3A4 (0.53) CYP3A4ALDH1A1BTK
SCHEMBL2127061 0.77 CYP3A4 (0.53) CYP3A4ALDH1A1MAPTHPGDPLA2G7
SCHEMBL2128872 0.76 CYP3A4 (0.57) CYP3A4ALDH1A1ABL1TRPV1MAPK1
SCHEMBL2128420 0.76 CYP3A4 (0.53) CYP3A4ALDH1A1MAPTLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885ALDH1A1 1136/4885MAPT 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.